CORRECTING and REPLACING Sucampo Standardizes on Veeva Vault for a Single Source of Truth and Enterprise-wide Capability
April 28 2016 - 10:44AM
Business Wire
High-growth biopharmaceutical company sets
content and information management foundation for greater speed,
agility, and compliance throughout the product lifecycle
Headline of release should read: Sucampo Standardizes on Veeva
Vault for a Single Source of Truth and Enterprise-wide Capability
(instead of Sucampo Standardizes on Veeva Vault for a Single Source
of Truth Enterprise-wide)
The corrected release reads:
SUCAMPO STANDARDIZES ON VEEVA VAULT FOR A
SINGLE SOURCE OF TRUTH AND ENTERPRISE-WIDE CAPABILITY
High-growth biopharmaceutical company sets
content and information management foundation for greater speed,
agility, and compliance throughout the product lifecycle
Veeva Systems (NYSE:VEEV) announced today that Sucampo
Pharmaceuticals (NASDAQ:SCMP), a fast-growing global
biopharmaceutical company, has standardized on the Veeva Vault
platform and suite of applications to provide a unified foundation
for content and information management. Veeva’s solution will help
Sucampo eliminate information and process siloes across functional
teams, regions, and partners, enabling Sucampo to make information
fully accessible and actionable. Veeva Vault allows Sucampo to
increase efficiency and strengthen compliance with a single source
of truth for content plus life sciences-specific solutions that
streamline key processes throughout the product lifecycle.
Sucampo’s move to Veeva Vault is the cornerstone of its
initiative to ensure greater efficiency and leverage valuable
information created at every stage of a product – including
clinical, quality, regulatory, and commercial. “There is a wealth
of insight that can be gleaned when you have end-to-end visibility
spanning the value chain,” explained Michael Gammons, Sucampo’s
chief information officer and vice president of information
technology. “As a rapidly growing company, it’s critical we set a
foundation for future growth by deploying industry-specific
applications that support our most crucial business functions, all
on one common platform. Veeva Vault is the foundation and provides
the process optimization and single source of truth we need for
agility and speed across the product lifecycle.”
Having valuable product information quickly accessible for
future use in all functional areas, plus key process metrics, can
have tremendous impact on the business. For instance, early-stage
analysis of a compound can be critical to compiling submissions
documents for licensing applications years later. With Veeva Vault,
all content and audit trails are in a central system of record,
reducing complexity and cost.
Veeva Vault also aligns with Sucampo’s corporate initiative to
leverage the efficiencies and agility of Veeva’s industry cloud.
“Our IT department is focused on solving business problems, and,
with Veeva Vault, we get a world-class technology foundation plus
tailored content and information management solutions that fit our
business. We don’t have infrastructure to manage or software we
need to customize,” said Gammons. “As important, Veeva provides
frequent enhancements so we’re always working with the latest
innovations instead of waiting years and investing more to
implement an incremental version upgrade.”
Over the coming months, Sucampo will drive an aggressive
implementation plan to rollout key Veeva Vault solutions worldwide
including: Vault eTMF for clinical trial master file management;
Vault QualityDocs for managing quality, manufacturing, and
validation documents; and Vault Submissions, part of the Vault RIM
suite, for regulatory submissions.
In related news today, Veeva introduced new innovative features
in its latest release of Veeva Vault, version 14, to empower life
sciences companies to streamline their business processes across an
increasingly complex ecosystem of internal and external
stakeholders. Read today’s press release about how the newest
release of Veeva Vault is helping to get products to market faster
and more efficiently.
Additional Information
For more on Veeva Vault, visit: veeva.com/vaultStay updated on
the latest Veeva news on LinkedIn:
linkedin.com/company/veeva-systemsFollow @veevasystems on Twitter:
twitter.com/veevasystemsLike Veeva on Facebook:
facebook.com/veevasystems
About Veeva Systems
Veeva Systems Inc. is a leader in cloud-based software for the
global life sciences industry. Committed to innovation, product
excellence, and customer success, Veeva has more than 400
customers, ranging from the world's largest pharmaceutical
companies to emerging biotechs. Veeva is headquartered in the San
Francisco Bay Area, with offices in Europe, Asia, and Latin
America. For more information, visit www.veeva.com.
Forward-looking Statements
This release contains forward-looking statements, including the
market demand for and acceptance of Veeva’s products and services,
the results from use of Veeva’s products and services, and general
business conditions, particularly in the life sciences industry.
Any forward-looking statements contained in this press release are
based upon Veeva’s historical performance and its current plans,
estimates, and expectations, and are not a representation that such
plans, estimates, or expectations will be achieved. These
forward-looking statements represent Veeva’s expectations as of the
date of this press announcement. Subsequent events may cause these
expectations to change, and Veeva disclaims any obligation to
update the forward-looking statements in the future. These
forward-looking statements are subject to known and unknown risks
and uncertainties that may cause actual results to differ
materially. Additional risks and uncertainties that could affect
Veeva’s financial results are included under the captions, “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations,” in the company’s filing on
Form 10-K for the period ended January 31, 2016. This is available
on the company’s website at veeva.com under the Investors section
and on the SEC’s website at sec.gov. Further information on
potential risks that could affect actual results will be included
in other filings Veeva makes with the SEC from time to time.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160428005595/en/
Veeva SystemsLisa Barbadora, 610-420-3413pr@veeva.com
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From Apr 2024 to May 2024
Sucampo Pharmaceuticals, Inc. (delisted) (NASDAQ:SCMP)
Historical Stock Chart
From May 2023 to May 2024